Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

178 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Plasma and albumin-free recombinant factor VIII: pharmacokinetics, efficacy and safety in previously treated pediatric patients.
Blanchette VS, Shapiro AD, Liesner RJ, Hernández Navarro F, Warrier I, Schroth PC, Spotts G, Ewenstein BM; rAHF-PFM Clinical Study Group. Blanchette VS, et al. Among authors: shapiro ad. J Thromb Haemost. 2008 Aug;6(8):1319-26. doi: 10.1111/j.1538-7836.2008.03032.x. Epub 2008 May 22. J Thromb Haemost. 2008. PMID: 18503631 Free article.
Minimal factor XIII activity level to prevent major spontaneous bleeds.
Menegatti M, Palla R, Boscarino M, Bucciarelli P, Muszbek L, Katona E, Makris M, Peyvandi F; PRO-RBDD study group. Menegatti M, et al. J Thromb Haemost. 2017 Sep;15(9):1728-1736. doi: 10.1111/jth.13772. Epub 2017 Aug 17. J Thromb Haemost. 2017. PMID: 28688221 Free article.
Classification of rare bleeding disorders (RBDs) based on the association between coagulant factor activity and clinical bleeding severity.
Peyvandi F, Di Michele D, Bolton-Maggs PH, Lee CA, Tripodi A, Srivastava A; Project on Consensus Definitions in Rare Bleeeding Disorders of the Factor VIII/Factor IX Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. Peyvandi F, et al. J Thromb Haemost. 2012 Sep;10(9):1938-43. doi: 10.1111/j.1538-7836.2012.04844.x. J Thromb Haemost. 2012. PMID: 22943259 Free article. No abstract available.
Characterization of the anti-factor VIII immunoglobulin profile in patients with hemophilia A by use of a fluorescence-based immunoassay.
Boylan B, Rice AS, Dunn AL, Tarantino MD, Brettler DB, Barrett JC, Miller CH; Hemophilia Inhibitor Research Study Investigators; Hemophilia Inhibitor Research Study Investigators. Boylan B, et al. J Thromb Haemost. 2015 Jan;13(1):47-53. doi: 10.1111/jth.12768. Epub 2014 Dec 11. J Thromb Haemost. 2015. PMID: 25354263 Free PMC article.
Recombinant factor IX Fc for the treatment of hemophilia B.
Ljung R, Matino D, Shapiro AD. Ljung R, et al. Among authors: shapiro ad. Eur J Haematol. 2024 May;112(5):678-691. doi: 10.1111/ejh.14176. Epub 2024 Feb 18. Eur J Haematol. 2024. PMID: 38369860 Review.
Long-term outcomes of prophylaxis with a recombinant factor VIII Fc or recombinant factor IX Fc in patients with hemophilia previously treated on demand.
Álvarez-Román MT, Shapiro AD, Ragni MV, Palmborg H, Bystrická L, Szamosi J, Casiano S, Chambost H. Álvarez-Román MT, et al. Among authors: shapiro ad. Res Pract Thromb Haemost. 2023 Aug 9;7(6):102163. doi: 10.1016/j.rpth.2023.102163. eCollection 2023 Aug. Res Pract Thromb Haemost. 2023. PMID: 37720484 Free PMC article.
Intracellular tPA-PAI-1 interaction determines VLDL assembly in hepatocytes.
Dai W, Zhang H, Lund H, Zhang Z, Castleberry M, Rodriguez M, Kuriakose G, Gupta S, Lewandowska M, Powers HR, Valmiki S, Zhu J, Shapiro AD, Hussain MM, López JA, Sorci-Thomas MG, Silverstein RL, Ginsberg HN, Sahoo D, Tabas I, Zheng Z. Dai W, et al. Among authors: shapiro ad. Science. 2023 Sep;381(6661):eadh5207. doi: 10.1126/science.adh5207. Epub 2023 Sep 1. Science. 2023. PMID: 37651538
178 results